Nicotinamide adenine dinucleotide — central coenzyme in cellular energy metabolism. Extensively studied for roles in aging, DNA repair, and mitochondrial function.
Varies by administration route; IV bolus cleared within hours
SKUs
3
Evidence
Moderate Evidence
NAD+ (nicotinamide adenine dinucleotide) is a molecule found in every cell in the body that sits at the center of how cells produce energy and repair DNA. In the 2010s, research in animals showed that NAD+ levels drop significantly with age — and that restoring them could reverse some of the metabolic decline associated with aging. That finding turned NAD+ into one of the most actively researched longevity targets. Researchers have since studied supplementation through IV infusions or precursor molecules like NMN and NR for aging-related decline, metabolic health, muscle function, and neurological protection.
Aging and Longevity Research
Animal studies consistently show that restoring NAD+ levels in aged animals improves metabolic function, endurance, and in some models extends lifespan. Human trials have focused on biomarker changes and functional outcomes. A key finding is that NAD+ levels in blood and muscle can be raised through supplementation with precursors.
Metabolic Health Research
Human trials have examined NAD+ precursors for effects on insulin sensitivity, body composition, and metabolic markers. Some trials show improvements in muscle function and reductions in fatigue, particularly in older adults.
Neurological Research
NAD+ supports how neurons generate energy inside their mitochondria, and it also activates a family of proteins called sirtuins — regulators that influence how genes respond to stress, how cells repair themselves, and how efficiently they age. Research is examining its role in conditions including Alzheimer's disease, peripheral neuropathy, and cognitive decline, with early clinical data emerging.
IV NAD+ Infusion Research
Giving NAD+ directly by IV bypasses the multi-step conversion that oral precursors require and raises blood NAD+ levels more rapidly. Practitioners have used IV NAD+ in contexts including addiction recovery support, energy restoration, and neurological recovery — though these uses are ahead of the formal trial evidence. Randomized controlled trials specifically examining IV-route benefits compared to oral precursors are limited, and this remains an active area of investigation.
NAD+ levels decline significantly with age — by roughly 50% between youth and middle age in many tissues.
Supplementation with NAD+ precursors (NMN, NR) raises blood and muscle NAD+ levels in human trials.
Human trials show improvements in muscle function, walking speed, and fatigue in older adults.
Animal studies show metabolic improvements and lifespan extension with NAD+ restoration.
Formal large randomized controlled trials in humans are ongoing but results are still emerging.
The most important open question is whether raising NAD+ levels in the blood actually translates into meaningful health improvements in humans — that connection has not been firmly established by large clinical trials. Most human trial evidence to date is from small, short-duration studies measuring biomarkers rather than clinical outcomes. Large confirmatory trials are still underway. IV NAD+ has less randomized trial support than oral precursors for most applications.
NAD+ is the molecule your cells use to extract energy from food through a process that happens inside mitochondria. It carries electrons from one reaction to the next in the energy production chain. When NAD+ levels are high, cells work efficiently and repair DNA promptly. When they drop — as they do with age, stress, and inflammation — energy production becomes less efficient and DNA damage accumulates. NAD+ also activates a family of proteins called sirtuins, which regulate gene expression in ways associated with stress resistance and metabolic efficiency. Supplementing NAD+ directly or through precursors like NMN and NR aims to restore the cellular energy and repair capacity that declines with aging.
NAD+ precursors (NMN, NR) are generally well-tolerated in human trials with no serious adverse effects reported. IV NAD+ infusions can cause flushing, nausea, chest tightness, and other transient symptoms during infusion, which are managed by slowing the infusion rate. No serious long-term safety signals have emerged in completed trials. It is not FDA-approved as a drug; oral precursors are sold as supplements.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
Oral: 250–1000mg/day studied; IV infusions: 250–1500mg per session in clinical studies
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.